[ad_1]
Horizon Therapeutics plc (Nasdaq:HPS) Announced today that the company’s overall reputation ranked first among the group of American patients reported to work with the company, and the company’s overall reputation ranked second among the group of American patients familiar with the company.These results are based on PatientView’s annual Polls Evaluated 207 US patient populations from 38 pharmaceutical and biotech companies.
Matt Flesch, vice president of patient advocacy and communications at Horizon said: “Our patient advocacy team is working with patient groups every day to support them in improving the lives of people with some of the most challenging diseases. The recognition of experienced patient groups and their insights have guided almost every aspect of our work, which is an honor. We are frustrated with the feedback provided in the PatientView report and hope to continue to get opportunities. Support transformative work led by patient advocacy organizations around the world. ”
U.S. report summary
The PatientView US report is based on an annual survey of the reputation of the pharmaceutical industry and individual companies from the perspective of the American patient population.
The report provides two sets of rankings: one group is based on feedback from the group that the report works with the company, and the other group is based on feedback from a group familiar with the company.
In the group of patients reported to work with Horizon, the company ranked first in the following areas:
-
Supporting patients during the COVID pandemic
-
Develop effective patient-centered strategies
-
Provide patients with high-quality information
-
Ensure patient safety
-
Provide quality products that are beneficial to patients
-
Act with integrity
-
Working with patient groups
-
Provide “beyond the pill” service
-
Involve patients in development
-
Be transparent in terms of prices, clinical trial data and stakeholders
The patient group familiar with the company ranks first in terms of effective patient-centered strategies, high-quality information for patients, and transparency of funding for stakeholders.
Global report summary
April 2021, Patient View report Worldwide Evaluate the reputation of the pharmaceutical industry and individual companies from the perspective of patient groups around the world.
-
Among the patient groups that Horizon has worked with, the company ranks second in overall corporate reputation and first in the following categories: acting with integrity, providing services “out of the pill” and providing high-quality patient information. The company ranks second in the support provided to patients in terms of the COVID-19 pandemic, patient centrality, and the quality of relationships with the patient population.
-
Among the group of patients who are familiar with the company, Horizon’s overall reputation ranks 4th, while the company that acts honestly ranks 2nd. The company also ranks third in terms of “beyond pill” services.
Horizon’s commitment to the disease community
Horizon is committed to improving people’s lives by identifying and delivering drugs that meet unmet medical needs; the company’s commitment to patients goes beyond its drugs. In 2020, Horizon is actively working with more than 100 organizations to raise awareness of many underrepresented diseases and to advocate on behalf of patients and their communities.
Highlights of the company since 2020 include:
- Announced investment of 1 million US dollars to establish #RAREis Scholarship Fund, The program launched in cooperation with the Everylife Rare Diseases Foundation aims to support adults with rare diseases to carry out rich life activities, including educational courses, travel allowances for rare disease conferences, and obtaining two-year and four-year degrees.
- Provided more than $1 million to patient organizations to support COVID-19 relief efforts Suitable for people with rare and rheumatic diseases.
- Hosted the company’s first ever “Patient Advocacy Summit” 45 advocates from 32 organizations gathered to collaborate on innovative ideas related to telemedicine. The summit produced a number of programs and resources supported by Horizon to increase access to telemedicine options for people with rare, autoimmune and severe inflammatory diseases. This includes providing support and providing computer and Internet access to people with rare diseases who would otherwise not be able to obtain such services.
- In collaboration with patient groups, launched the first ever Thyroid Eye Disease (TED) Awareness Week, Make people aware of this serious, progressive, and rare autoimmune disease. These include the release of TED Today, a five-episode online talk show hosted by Horizon’s “Listen to Your Eyes” patient community.
- Created #RAREis Year of Rare Young Adult To empower young people with rare diseases to talk about and seek support for the unique experience of this age group, and discuss these pressing issues with Horizon employees.
- Sponsored and participated in the “Virtual Walk to Heal Arthritis” event of the Arthritis Foundation, A total of 560 Horizon employees participated, raising more than $130,000 for the organization.
About Horizon
Horizon focuses on the discovery, development and commercialization of drugs that meet the critical needs of people affected by rare, autoimmune and severe inflammatory diseases. Our channels are purposeful: we use scientific expertise and courage to bring clinically meaningful treatments to patients. We believe that science and compassion must work together to change lives.For more information on how we do everything we can to affect our lives, please visit www.horizontherapeutics.com And follow us Twitter, LinkedIn, Instagram with Facebook.
View the source code version on businesswire.com: https://www.businesswire.com/news/home/20210513005750/zh/
[ad_2]
Source link
